BIO-TECHNE Corp vs Uber Technologies Inc — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while Uber Technologies Inc trades at $71.61 (market cap $146.91B). The key difference: Uber Technologies Inc is far larger — about 13.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| TECH | UBER | |
|---|---|---|
Market Cap | $11.16B | $146.91B |
Sector | Health | Industrials |
52-Week High | $72.12 | $100.10 |
52-Week Low | $43.31 | $68.61 |
Enterprise Value | $11.24B | $153.24B |
Dividend Yield | 0.45% | — |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Uber's stock trades at $72.46, down 2.13% on the day, reflecting near-term pressure amid a bearish technical signal. Fundamentally, the company shows strong revenue growth, with 2025 revenue reaching $52.02 billion and net income of $10.05 billion, though profitability margins have moderated from 2024 peaks. Recent news highlights strategic shifts toward autonomous vehicles, including robotaxi pilots in Europe and cost-cutting measures like HR layoffs and AI spending caps to improve efficiency.
The outlook remains positive with an 81.67% analyst buy rating and a $107.64 consensus price target, suggesting significant upside. Key risks include execution challenges in autonomous vehicle integration, competitive pressures in key markets like India, and potential margin compression. Investors should weigh strong cash flow generation and market leadership against evolving regulatory and technological landscapes.
Trailing returns across standard periods
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →